S&P 500   4,172.13 (-0.79%)
DOW   32,801.28 (-0.73%)
QQQ   347.46 (-0.72%)
AAPL   178.79 (+0.84%)
MSFT   329.08 (-0.64%)
META   262.22 (-0.11%)
GOOGL   123.22 (-0.36%)
AMZN   119.52 (-1.76%)
TSLA   196.97 (-2.08%)
NVDA   386.46 (-3.65%)
NIO   7.30 (-1.48%)
BABA   78.16 (-0.65%)
AMD   119.62 (-4.51%)
T   15.79 (+0.96%)
F   12.02 (-4.53%)
MU   68.19 (-4.88%)
CGC   0.81 (-4.85%)
GE   100.04 (-2.30%)
DIS   87.30 (-0.59%)
AMC   4.45 (-3.89%)
PFE   37.60 (+1.59%)
PYPL   61.46 (-0.95%)
NFLX   393.04 (+0.02%)
S&P 500   4,172.13 (-0.79%)
DOW   32,801.28 (-0.73%)
QQQ   347.46 (-0.72%)
AAPL   178.79 (+0.84%)
MSFT   329.08 (-0.64%)
META   262.22 (-0.11%)
GOOGL   123.22 (-0.36%)
AMZN   119.52 (-1.76%)
TSLA   196.97 (-2.08%)
NVDA   386.46 (-3.65%)
NIO   7.30 (-1.48%)
BABA   78.16 (-0.65%)
AMD   119.62 (-4.51%)
T   15.79 (+0.96%)
F   12.02 (-4.53%)
MU   68.19 (-4.88%)
CGC   0.81 (-4.85%)
GE   100.04 (-2.30%)
DIS   87.30 (-0.59%)
AMC   4.45 (-3.89%)
PFE   37.60 (+1.59%)
PYPL   61.46 (-0.95%)
NFLX   393.04 (+0.02%)
S&P 500   4,172.13 (-0.79%)
DOW   32,801.28 (-0.73%)
QQQ   347.46 (-0.72%)
AAPL   178.79 (+0.84%)
MSFT   329.08 (-0.64%)
META   262.22 (-0.11%)
GOOGL   123.22 (-0.36%)
AMZN   119.52 (-1.76%)
TSLA   196.97 (-2.08%)
NVDA   386.46 (-3.65%)
NIO   7.30 (-1.48%)
BABA   78.16 (-0.65%)
AMD   119.62 (-4.51%)
T   15.79 (+0.96%)
F   12.02 (-4.53%)
MU   68.19 (-4.88%)
CGC   0.81 (-4.85%)
GE   100.04 (-2.30%)
DIS   87.30 (-0.59%)
AMC   4.45 (-3.89%)
PFE   37.60 (+1.59%)
PYPL   61.46 (-0.95%)
NFLX   393.04 (+0.02%)
S&P 500   4,172.13 (-0.79%)
DOW   32,801.28 (-0.73%)
QQQ   347.46 (-0.72%)
AAPL   178.79 (+0.84%)
MSFT   329.08 (-0.64%)
META   262.22 (-0.11%)
GOOGL   123.22 (-0.36%)
AMZN   119.52 (-1.76%)
TSLA   196.97 (-2.08%)
NVDA   386.46 (-3.65%)
NIO   7.30 (-1.48%)
BABA   78.16 (-0.65%)
AMD   119.62 (-4.51%)
T   15.79 (+0.96%)
F   12.02 (-4.53%)
MU   68.19 (-4.88%)
CGC   0.81 (-4.85%)
GE   100.04 (-2.30%)
DIS   87.30 (-0.59%)
AMC   4.45 (-3.89%)
PFE   37.60 (+1.59%)
PYPL   61.46 (-0.95%)
NFLX   393.04 (+0.02%)
NASDAQ:ATNX

Athenex (ATNX) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
$0.20
$1.76
52-Week Range
N/A
Volume
1.88 million shs
Average Volume
194,316 shs
Market Capitalization
$1.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ATNX stock logo

About Athenex (NASDAQ:ATNX) Stock

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Receive ATNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.

ATNX Stock News Headlines

The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
Athenex files Chapter 11
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
Athenex Files For Chapter 11 Bankruptcy
Athenex (ATNX) Upgraded to Buy: Here's Why
Athenex Announces a Reverse Stock Split
Athenex Announces MHRA Decision on Oral Paclitaxel
See More Headlines

Receive ATNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.

ATNX Company Calendar

Last Earnings
11/04/2021
Today
5/31/2023
Next Earnings (Estimated)
7/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATNX
Fax
N/A
Employees
652
Year Founded
N/A

Profitability

Net Income
$-103,430,000.00
Pretax Margin
-95.92%

Debt

Sales & Book Value

Annual Sales
$102.82 million
Book Value
($3.07) per share

Miscellaneous

Free Float
7,866,000
Market Cap
$1.76 million
Optionable
Optionable
Beta
1.36

Key Executives

  • Yiu Nam Lau
    Chairman & Chief Executive Officer
  • Jeff Yordon
    COO & President-Athenex Pharmaceutical Division
  • Joe Annoni
    Chief Financial Officer
  • Darrel P. Cohen
    Chief Medical Officer
  • William Zuo
    President-China Operations













ATNX Stock - Frequently Asked Questions

Should I buy or sell Athenex stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ATNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATNX, but not buy additional shares or sell existing shares.
View ATNX analyst ratings
or view top-rated stocks.

When is Athenex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our ATNX earnings forecast
.

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.08. The firm had revenue of $32.30 million for the quarter, compared to analysts' expectations of $19.40 million. Athenex had a negative net margin of 86.31% and a negative trailing twelve-month return on equity of 727.79%. During the same quarter in the prior year, the firm earned ($0.44) EPS.

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

When did Athenex IPO?

(ATNX) raised $72 million in an initial public offering (IPO) on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

Who are Athenex's major shareholders?

Athenex's stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (8.96%), Alyeska Investment Group L.P. (1.15%), BlackRock Inc. (0.77%), UBS Group AG (0.77%), Acadian Asset Management LLC (0.73%) and Renaissance Technologies LLC (0.68%). Insiders that own company stock include Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan and William Wei Zuo.
View institutional ownership trends
.

How do I buy shares of Athenex?

Shares of ATNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Athenex make?

Athenex (NASDAQ:ATNX) has a market capitalization of $0.00 and generates $102.82 million in revenue each year. The company earns $-103,430,000.00 in net income (profit) each year or ($15.88) on an earnings per share basis.

How many employees does Athenex have?

The company employs 652 workers across the globe.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The official website for the company is www.athenex.com. The company can be reached via phone at (716) 427-2950 or via email at stevenrubis@athenex.com.

This page (NASDAQ:ATNX) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -